US biopharma company Palatin Technologies (NYSE American: PTN) is at risk of being removed from the NYSE American exchange ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

Technologies announced today that on April 10, NYSE American publicly announced and provided a notice to the company that NYSE ...

NYSE American LLC ("NYSE American" or the "Exchange") announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Palatin Technologies, Inc. ...

CRANBURY, N.J., April 10, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of ...

(RTTNews) - Palatin Technologies, Inc. (PTN), Thursday announced positive data from the Phase 2b BREAKOUT study of a melanocortin agonist in patients with diabetic Type 2 nephropathy. The six ...

US drug developer Palatin Technologies (NYSE American: PTN) announced that its BMT-801 Phase II obesity co-administration ...

CRANBURY, N.J. - Palatin Technologies, Inc. (NYSE American: PTN), a small-cap biotech company with a market capitalization of $11.5 million, revealed significant clinical improvements in patients ...

NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Palatin ...

A third of patients with active ulcerative colitis (UC) experienced clinical remission in a Phase II trial of Palatin ...

Palatin Technologies, Inc. (the "Company") (NYSE American:PTN), a biopharmaceutical company developing first-in-class ...